4.5 Article

Association Between Attention-Deficit/Hyperactivity Disorder and Sleep Impairment in Adulthood: Evidence From a Large Controlled Study

Journal

JOURNAL OF CLINICAL PSYCHIATRY
Volume 70, Issue 11, Pages 1523-1529

Publisher

PHYSICIANS POSTGRADUATE PRESS
DOI: 10.4088/JCP.08m04514

Keywords

-

Funding

  1. Abbott
  2. Alza
  3. Cephalon
  4. Eli Lilly
  5. Hilda and Preston Davis Foundation
  6. McNeil
  7. Merck
  8. New River
  9. National Institutes of Health (NIH) [R01MH57934]
  10. AstraZeneca
  11. Bristol-Myers Squibb
  12. Organon
  13. Otsuka
  14. Shire
  15. National Institute of Child Health and Human Development
  16. Celltech
  17. Glaxo
  18. Gliatech
  19. Janssen
  20. NARSAD
  21. National Institute on Drug Abuse
  22. NeuroSearch
  23. Pfizer
  24. Pharmacia
  25. The Prechter Foundation
  26. The Stanley Foundation
  27. UCB Pharma
  28. Wyeth
  29. Ortho-McNeil-Janssen SA
  30. Shire Pharmaceuticals

Ask authors/readers for more resources

Objective: To examine whether sleep impairment is associated with attention-deficit/hyperactivity disorder (ADHD) in adults. Method: In a study conducted from 1998 to 2003, we identified sleep characteristics in a community sample of 182 cases of DSM-IV ADHD or ADHD not otherwise specified and 117 non-ADHD controls aged 18 to 55 years. Attention-deficit/hyperactivity disorder status, current and lifetime psychiatric comorbidity, and pharmacologic treatment of ADHD were identified with the Structured Clinical Interview for DSM-IV and with modules from the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version. Sleep problems were characterized by self-report. We separately accounted for the contribution of age at ADHD onset, ADHD pharmacotherapy, lifetime bipolar disorder, and the following lifetime and current comorbidities: depression, generalized anxiety, substance abuse, and multiple anxiety disorders. Results: Adults with ADHD went to bed later than control subjects and had a wider range of bedtimes (mean +/- SD = 18 +/- 92 min vs 54 +/- 69 min before midnight; P < .001), were more likely to take over an hour to fall asleep (OR = 5.22, P = .001), and were more likely (P < .003) to experience difficulty going to bed, going to sleep, sleeping restfully, or waking in the morning. Adults with ADHD experienced daytime sleepiness more often (OR = 2.23, P = .003) and reported more sleep problems (mean +/- SD = 6.7 +/- 2.5 vs 4.3 +/- 2.2; P < .001) than controls. All sleep impairments were significantly associated with ADHD independent of contributions to sleep disruption from ADHD pharmacotherapy, comorbidities likely to contribute to sleep disturbance, and age at ADHD onset. Conclusion: Sleep disturbances that are not attributable to comorbid mental health conditions or ADHD pharmacotherapy are associated with ADHD in adulthood. Clinicians and researchers should consider the potential contribution of sleep disruption to the clinical presentation of adults with ADHD. J Clin Psychiatry 2009,70(11):1523-1529 (C) Copyright 2009 Physicians Postgraduate Press, Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available